Westlake Village-based Sienna Biopharmaceuticals reported a nearly 15 percent drop in its operating expenses for the quarter ended March 31, as it decreased research and development spending to move products through clinical trials. The pre-revenue company, which develops dermatological therapies, marked the quarter with an “End-of-Phase 2 meeting” with the U.S. Food and Drug Administration…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
